Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant gram-negative bacterial infections: a prospective observational multicenter study

观察研究 碳青霉烯 医学 药效学 多粘菌素 药代动力学 抗生素 克 重症监护医学 药理学 内科学 微生物学 生物 细菌 遗传学
作者
Zhenwei Yu,Huangdu Hu,Xiaofen Liu,Jieqiong Liu,Lingyan Yu,Anqi Wei,Chuanwei Xin,Yongxiong Gan,Lei Shu,Li Zhuang,Yanfei Shen,Xiaoxing Du,Zhu Jianping,Yi Yan Yang,Gang Liang,Feng Guo,Jing Zhang,Yunsong Yu
出处
期刊:Antimicrobial Agents and Chemotherapy [American Society for Microbiology]
卷期号:69 (4): e0185924-e0185924 被引量:5
标识
DOI:10.1128/aac.01859-24
摘要

Polymyxin B, a last resort for carbapenem-resistant gram-negative bacteria (CRGNB) infections, has infection site-specific pharmacokinetic/pharmacodynamic (PK/PD) properties. However, there is little clinical evidence to support optimal exposures of polymyxin B for different site infections. We performed a prospective, observational, multicenter study to evaluate the clinical outcomes and PK/PD of intravenous polymyxin B treatment for various site CRGNB infections. The main clinical outcomes were 14-day all-cause mortality and nephrotoxicity, and the secondary outcomes were 28-day mortality and clinical response. The area under curves (AUCs) of polymyxin B were determined, and their associations with clinical outcomes were analyzed by stratification based on the infection site. A total of 312 patients were ultimately enrolled from 10 research centers. The overall 14-day mortality was 29.5%, and those of patients with lower respiratory tract infection (LRTI), intra-abdominal infection (IAI), and bloodstream infection (BSI) were 32.3%, 19.7%, and 30.3%, respectively. The 28-day mortality rate was 38.1%, while LRTI patients had the highest mortality (41.4%) and IAI patients lowest (34.8%). The clinical response rate was 46.2%, which was similar among the subgroups. The overall AKI rate was 60.9%. An AUC greater than 50 mg∙h/L was related to lower mortality in IAI patients but not in LRTI patients, which led to a lower but not significant difference in the overall analysis. The AUC of polymyxin B was an independent risk factor for 14-day mortality in IAI patients, and the cutoff value was 76 mg∙h/L. The results would be helpful for personalized dosing and monitoring of polymyxin B.CLINICAL TRIALSThis study is registered with the Chinese Clinical Trial Registry as ChiCTR2200056667.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cdercder的应助被SCM采纳,获得10
刚刚
刚刚
强小强努力努力完成签到,获得积分10
1秒前
Lachryz发布了新的文献求助10
1秒前
凉介发布了新的文献求助10
1秒前
1秒前
笑点低幻珊完成签到,获得积分10
2秒前
积极的含灵完成签到,获得积分20
2秒前
先进的冰海完成签到,获得积分10
3秒前
刘龙完成签到,获得积分0
3秒前
123完成签到,获得积分10
3秒前
段启瑞完成签到,获得积分10
4秒前
桐桐的应助被王宏伟采纳,获得10
5秒前
天天快乐的应助被景胜杰采纳,获得20
5秒前
5秒前
水弘的应助被制作人采纳,获得10
5秒前
赘婿的应助被小马采纳,获得10
5秒前
元吉的应助被赵彬旭采纳,获得10
6秒前
呆萌尔风发布了新的文献求助20
6秒前
zhang发布了新的文献求助10
6秒前
Hello的应助被fzkls采纳,获得10
6秒前
Hsia完成签到,获得积分10
7秒前
7秒前
科研通AI6.4的应助被高高亦采纳,获得10
8秒前
零度完成签到 ,获得积分10
8秒前
9秒前
英俊的铭的应助被一点漾洋采纳,获得50
9秒前
冷艳的寒天的应助被jinrui采纳,获得10
9秒前
H欢完成签到,获得积分10
9秒前
稳稳完成签到,获得积分10
9秒前
Lucycomplex完成签到,获得积分10
9秒前
qi发布了新的文献求助10
10秒前
10秒前
CAOHOU的应助被qsyslh采纳,获得10
11秒前
蒲公英发布了新的文献求助10
12秒前
dery完成签到 ,获得积分10
12秒前
凉介完成签到,获得积分10
13秒前
CocoGabrielle发布了新的文献求助10
13秒前
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187592
求助须知:如何正确求助?哪些是违规求助? 9575705
关于积分的说明 21842471
捐赠科研通 7785407
什么是DOI,文献DOI怎么找? 3435057
关于科研通互助平台的介绍 2559461
邀请新用户注册赠送积分活动 2481952